This Business Course is being held in Frankfurt, Germany on the 03 September 2012 at 18:00-20:30

Price: Enal Razvi Managing Director, Select Biosciences Inc

This course is designed to provide a review of the technical and commercial trends in the development and utilization of companion diagnostics for personalized medicine. Also covered here are the concept of circulating biomarkers, and the current state of development of this biomarker class and growth opportunities.

Personalized Medicine	Companion Diagnostics (CDx)	Circulating Biomarkers
Development of Companion Diagnostics and Therapeutics Disease Classes where CDx/Rx Combinations have been developed Current State of Personalized Medicine Field
Competitive Environment Market Metrics
Emerging Classes of Biomarkers and their Potential Utility Circulating Biomarkers for Disease

This training course is ideally suited for researchers involved in work on biomarkers as well as companies seeking an entry into the biomarkers/CDx spaces, and requiring an in-depth view of the trends in the field both from a technical and commercial perspective—both academic as well as from the industrial community. Also, this course is important for biotechnology, pharmaceutical, and related disciplines wherein industry participants—both technically focused as well as business focused—can get a solid understanding of the marketplace as well as receive the most up-to-date market data and associated materials for in-house research and business planning activities.  Also, this course is recommended for investors as well as attorneys looking for a current technology and market review of this expanding field.

All attendees to this training course receive the electronic files of the presentation material on disk with full rights to use them in their internal R&D as well as business planning activities.

Training Course Specific Presentation Topics

• Cancer Personalized Medicine: A Driver for the Field of Companion Diagnostics and Therapeutics
• Current Status of the Personalized Medicine Space
• Stakeholders
• CDx/Rx Combinations and Growth Opportunities
• US FDA and EMEA Regulatory Stance
• Challenges and Drivers
  
• MicroRNAs as Circulating Biomarkers for Disease
• Diagnostics
• Therapeutics
  
• Epigenetic Markets for Disease
• Development as Diagnostic Biomarkers
• Utility for Therapeutics Development
  

For more information about this training course or for group registrations, please e-mail Kathy Gray at Kathy.Gray@SelectBiosciences.com